Study study type PathologyT1T0Patientssample sizesROB Results

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus etoposide plus platin
durvalumab plus etoposide and platin
CASPIAN (D ; all population), 2019
  NCT03043872
RCTExtensive stage SCLC (Es-SCLC) - 1st Line (L1)durvalumab, etoposide plus either cisplatin or carboplatinetoposide plus either cisplatin or carboplatinadults with untreated extensive-stage small-cell lung cancer as First-line treatment268 / 269some concern
conclusif
  • demonstrated 27 % decrease in deaths (OS) (PE)
  • suggested 25 % decrease in deaths (OS) (extension)
  • suggested 20 % decrease in PFS (extension)
  • suggested 22 % decrease in progression or deaths (PFS)